Hoang Van T, Yan Thomas J, Cavanaugh Jane E, Flaherty Patrick T, Beckman Barbara S, Burow Matthew E
Department of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
Department of Pharmacological Sciences, Division of Medicinal Chemistry, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA.
Cancer Lett. 2017 Apr 28;392:51-59. doi: 10.1016/j.canlet.2017.01.034. Epub 2017 Jan 30.
Mitogen-activated protein kinases (MAPKs) regulate diverse cellular processes including proliferation, cell survival, differentiation, and apoptosis. While conventional MAPK constituents have well-defined roles in oncogenesis, the MEK5 pathway has only recently emerged in cancer research. In this review, we consider the MEK5 signaling cascade, focusing specifically on its involvement in drug resistance and regulation of aggressive cancer phenotypes. Moreover, we explore the role of MEK5/ERK5 in tumorigenesis and metastatic progression, discussing the discrepancies in preclinical studies and assessing its viability as a therapeutic target for anti-cancer agents.
丝裂原活化蛋白激酶（MAPKs）调节多种细胞过程，包括增殖、细胞存活、分化和凋亡。虽然传统的MAPK成分在肿瘤发生中具有明确的作用，但MEK5通路直到最近才在癌症研究中出现。在这篇综述中，我们考虑MEK5信号级联，特别关注其在耐药性和侵袭性癌症表型调节中的作用。此外，我们探讨了MEK5/ERK5在肿瘤发生和转移进展中的作用，讨论临床前研究中的差异，并评估其作为抗癌药物治疗靶点的可行性。
